Adenovirus-mediated wt-p16 reintroduction induces cell cycle arrest or apoptosis in pancreatic cancer

J Calbó1, M Marotta, M Cascalló

  • 1Department of Biochemistry and Molecular Biology, University of Barcelona, Barcelona, Spain.

Cancer Gene Therapy
|November 1, 2001
PubMed

Insights

Gene replacement therapy using p16 (inhibitor of cyclin-dependent kinases CDK4/CDK6) shows promise for pancreatic cancer. Overexpressing p16 reduced tumor cell proliferation and inhibited tumor growth in vivo.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Pancreatic cancer has a poor prognosis, necessitating novel therapeutic strategies.
  • Inactivation of the p16 (INK4a/CDKN2) tumor suppressor gene is a frequent event in pancreatic cancer.
  • p16 inhibits cyclin-dependent kinases CDK4 and CDK6, making it a target for gene therapy.

Purpose of the Study:

  • To investigate the therapeutic potential of p16 gene replacement in pancreatic cancer.
  • To evaluate the effects of p16 overexpression on pancreatic cancer cell lines and xenografts.

Main Methods:

  • Transfection of human pancreatic tumor cell lines (NP-9, NP-18, NP-29, NP-31) with a recombinant adenovirus carrying wt-p16 cDNA (Ad5RSV-p16).
  • Assessment of cell proliferation, G1 arrest, senescence, and apoptosis.
  • Evaluation of tumor growth inhibition in subcutaneous pancreatic xenografts.

Main Results:

  • p16 overexpression decreased proliferation in all tested pancreatic cancer cell lines.
  • G1 arrest and senescence were observed in three cell lines, while one exhibited increased apoptosis.
  • Differential cellular responses may correlate with E2F-1 expression levels.
  • In vivo experiments confirmed p16's effectiveness in inhibiting pancreatic tumor growth.

Conclusions:

  • p16 gene replacement is a promising therapeutic approach for pancreatic cancer.
  • The study highlights the potential of targeting the p16 pathway for improved treatment outcomes.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...